Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Cantharidin analogues as protein phosphatase inhibitors: use in cancer therapy

Feb. 23, 2000

Cell Pathways presents apoptosis-promoting compounds

Feb. 23, 2000

NCI begins phase II trial of O6-benzylguanine/carmustine as glioma therapy

Feb. 23, 2000

Inhibitors of protein prenyltransferases remain a focus of R&D at Merck

Feb. 22, 2000

SBIR grant awarded to NeoRx for lymphoma radioimmunotherapy research

Feb. 22, 2000

Cantab reports anticancer potential for OX-40 ligand

Feb. 22, 2000

The Liposome Company meets with FDA to discuss Evacet NDA

Feb. 21, 2000

Pierre Fabre designs structurally novel inhibitors of protein prenylation

Feb. 18, 2000

New prostate cancer therapy to be studied in men with no other effective treatment options

Feb. 18, 2000

New series of taxanes designed at BMS

Feb. 18, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026